IPO

Medtronic Global Holdings S.C.A. has closed a registered public offering of €500,000,000 principal amount of Floating Rate Senior Notes due 2021, €1,500,000,000 principal amount of 0.000% Senior Notes due 2021, €1,500,000,000 principal amount of 0.375% Senior Notes due 2023, €1,500,000,000 principal amount of 1.125% Senior Notes due 2027, €1,000,000,000 principal amount of 1.625% Senior Notes due 2031 and €1,000,000,000 principal amount of 2.250% Senior Notes due 2039.

Medtronic plc today announced the pricing terms of the previously-announced cash tender offers by its wholly-owned subsidiaries, Medtronic, Inc. and Covidien International Finance S.A. (“CIFSA” and, together with Medtronic, Inc., the “Offerors”), for any and all (the “Any and All Tender Offers”) of the $3.1 billion in aggregate principal amount of the outstanding Notes

Medtronic plc today announced that, pursuant to the previously-announced cash tender offers

Coming off its record-breaking initial public offering (IPO) in December, where it raised $604.3 million, Moderna released its fourth-quarter financials, outlining an ambitious company buzzing with activity.

Medtronic Global Holdings S.C.A., has priced an offering of €500,000,000 principal amount of floating rate senior notes due 2021, €1,500,000,000 principal amount of 0% senior notes due 2021, €1,500,000,000 principal amount of 0.375% senior notes due 2023, €1,500,000,000 principal amount of 1.125% senior notes due 2027, €1,000,000,000 principal amount of 1.625% senior notes due 2031, and €1,000,000,000 principal amount of 2.250% senior notes due 2039.

Medtronic plc announced the upsizing of the previously-announced cash tender offers by its wholly-owned subsidiaries, Medtronic, Inc.

Lonza announced the adjustment of its Mid-Term Guidance 2022 to reflect the divestment of its former Water Care business unit and to emphasize Lonza’s focus on growth along the Healthcare Continuum®.

A summary of IPOs from companies in the biotech and pharma world since March 1, 2019.

Durham, NC-based Precision BioSciences filed on Friday with the U.S. Securities Exchange Commission for an initial public offering (IPO). The company, which focuses on gene-edited CAR-T cell therapies for cancer, plans to raise $100 million.

Lonza announced the completion of the divestment of its former Water Care business and operations to Platinum Equity for USD 630 million.